Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,462.00    -5.00 (-0.34%)
Bid:
1,468.00
Ask:
1,469.00
Spread: 1.00 (0.068%)
Market Cap: £3.09b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

10 Apr 2018 14:34

RNS Number : 4612K
Hikma Pharmaceuticals Plc
10 April 2018
Β 

Β 

Hikma Pharmaceuticals PLC - EIP Awards

LONDON, 10 April 2018: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards on 10 April 2015 under the 2014 Executive Incentive Plan ("EIP") which was completed on10 April 2018. These awards were automatically exercised by operation of the conditional award and vesting process. The exercise price under the EIP is Β£nil.

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Bassam Kanaan

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Shares acquired from vesting of the conditional awards on10 April 2018 under the EIP.

c)

Price(s) and volume(s)

Price(s): Β£nil

Volume(s): 19,945

d)

Aggregated information

N/A

e)

Date of the transaction

10 April 2018

f)

Place of the transaction

London Stock Exchange (XLON)

Β 

Khalid Nabilsi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Khalid Nabilsi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Shares acquired from vesting of the conditional awards on10 April 2018 under the EIP.

c)

Price(s) and volume(s)

Price(s): Β£nil

Volume(s): 14,165

d)

Aggregated information

N/A

e)

Date of the transaction

10 April 2018

f)

Place of the transaction

London Stock Exchange (XLON)

Riad Mishlawi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Riad Mishlawi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Shares acquired from vesting of the conditional awards on10 April 2018 under the EIP.

c)

Price(s) and volume(s)

Price(s): Β£nil

Volume(s): 13,811

d)

Aggregated information

N/A

e)

Date of the transaction

10 April 2018

f)

Place of the transaction

London Stock Exchange (XLON)

Β 

Β 

Majda Labadi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Majda Labadi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Shares acquired from vesting of the conditional awards on10 April 2018 under the EIP.

c)

Price(s) and volume(s)

Price(s): Β£nil

Volume(s): 10,089

d)

Aggregated information

N/A

e)

Date of the transaction

10 April 2018

f)

Place of the transaction

London Stock Exchange (XLON)

Β 

Peter SpeirsCompany Secretary, responsible for releasing this announcement+44 (0) 20 7399 2760

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
DSHBXGDSXXBBGIG
Date   Source Headline
29th May 20149:40 amRNSDirector/PDMR Shareholding
28th May 201412:00 pmRNSAcquisition
27th May 20149:53 amRNSDirector/PDMR Shareholding
15th May 20143:05 pmRNSResults of AGM
15th May 20147:00 amRNSInterim Management Statement
6th May 20141:03 pmRNSDirector/PDMR Shareholding
17th Apr 20144:41 pmRNSAnnual Information Update
14th Apr 20145:28 pmRNSDirector/PDMR Shareholding
7th Apr 20145:28 pmRNSBlocklisting Interim Review
7th Apr 20144:27 pmRNSTotal Voting Rights
2nd Apr 20147:00 amRNSSuccessful resolution to US FDA warning letter
24th Mar 201410:23 amRNSDirector/PDMR Shareholding
12th Mar 20147:10 amRNSDirectorate Change
12th Mar 20147:00 amRNSFinal Results
27th Feb 20142:35 pmRNSNotification of major interests in shares
21st Feb 201410:24 amRNSBlock Listing of Shares
14th Feb 20147:00 amRNSTrading Statement
30th Dec 20139:50 amRNSDirector/PDMR Shareholding
20th Dec 20134:23 pmRNSDirector/PDMR Shareholding
20th Dec 20131:58 pmRNSDirector/PDMR Shareholding
16th Dec 20137:00 amRNSTotal Voting Rights
13th Dec 20137:00 amRNSHolding(s) in Company
20th Nov 20137:00 amRNSRe Agreement
11th Nov 20134:55 pmRNSDirector/PDMR Shareholding
8th Nov 20133:04 pmRNSDirector/PDMR Shareholding
8th Nov 20137:00 amRNSInterim Management Statement
25th Oct 20134:13 pmRNSDirector/PDMR Shareholding
23rd Oct 201311:40 amRNSHolding(s) in Company
18th Oct 20134:55 pmRNSDirector/PDMR Shareholding
4th Oct 20132:01 pmRNSDividend Declaration
1st Oct 201311:27 amRNSBlocklisting Interim Review
1st Oct 201311:22 amRNSTotal Voting Rights
18th Sep 20137:00 amRNSHikma entering Ethiopian pharmaceutical market
2nd Sep 20133:06 pmRNSTransaction in Own Shares
29th Aug 201311:10 amRNSTransaction in Own Shares
21st Aug 20137:00 amRNSInterim Results
31st Jul 20133:41 pmRNSDirector/PDMR Shareholding
19th Jul 20139:40 amRNSTotal Voting Rights
8th Jul 20137:00 amRNSTrading Statement
5th Jul 20134:21 pmRNSHolding(s) in Company
1st Jul 20137:00 amRNSSigning of Exclusive Agreement with Theravance
20th Jun 20133:16 pmRNSDirector/PDMR Shareholding
3rd Jun 201311:24 amRNSTotal Voting Rights
28th May 20135:24 pmRNSHolding(s) in Company
23rd May 20134:59 pmRNSDirector/PDMR Shareholding
21st May 20133:36 pmRNSDirector/PDMR Shareholding
20th May 20139:42 amRNSDirector/PDMR Shareholding
16th May 20133:32 pmRNSResult of AGM
16th May 20137:00 amRNSInterim Management Statement
10th May 20133:05 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.